Biceltis 440mg Injection consists of Trastuzumab as an active constituent, which is indicated for its use in HER 2 breast cancer. In HER 2 positive patients, the breast cancer cells are mostly composed of HER2 proteins that cause rapid development of cancer tumours by serving as a signal to the cancerous. This medication is also used to treat metastatic gastric cancer with increased levels of HER2 proteins.

HER 2-positive breast cancer is most aggressive in nature. The targeted therapy for her 2 positive breast cancer works by selectively targeting the proteins that are responsible for the growth, development, and spread of cancer. Use effective birth control during the treatment and for at least 7 months after the final dose.

Biceltis 440mg Injection is not recommended for patients aged under 18 and patients who have severe breathing problems or need oxygen treatment. It is necessary to let your physician know if you have any heart problems, breathlessness, or have ever had any other cancer treatment. Make sure you inform your physician of all the medicines, including supplements and herbal medicines, you are taking before you start treatment with this medication.

Advanced and metastatic breast cancer

Metastatic gastric cancer

The protein called HER2 (human epidermal growth factor receptor 2) is found in abundant amounts on the surface of certain cancer cells, where it stimulates cancer growth. Trastuzumab selectively binds to HER2 and stops the growth of cancer cells.

Biceltis 440mg Injection shall either be administered before or after surgery.

It will be given as an Intravenous infusion for 90 minutes, if well tolerated it shall be administered within 30 minutes for the next doses.

Heart Problems

Allergic reactions

Kidney problems

Breathing difficulties

Fever

Visual disturbances

Nose bleeds or runny nose

Hair loss

Dizziness

Nail disorders

Weight loss

Loss of appetite

Bruising

Dry mouth

Liver inflammation

Muscle pain

Asthma/ lung disorders

Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional and vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with Biceltis 440mg Injection and cause undesirable side effects.

Keep Biceltis 440mg Injection out of sight and reach of children.

Store between 2˚C and 8˚C.

It is suggested to inform your doctor if you have a history of allergic reactions to Biceltis 440mg Injection to avoid life-threatening complications. If you have a history of lung disorder or breathing problems inform your doctor beforehand before the treatment commencement. Avoid planning for pregnancy and breastfeeding for a minimum of 7 months after the last dose. Monitor your heart parameters regularly during the treatment with Biceltis 440mg Injection as it may impact the functioning of heart.